A successful acquisition strategy goes beyond the highest bid. It involves 'thinking like the molecule'—evaluating which buyer has the specific expertise, capabilities, and cultural alignment to best steward the asset's development. This reframes M&A from a financial transaction to a decision about the asset's future.

Many M&A teams focus solely on closing the deal, a critical execution task. The best acquirers succeed by designing a parallel process where integration planning and value creation strategies are developed simultaneously with due diligence, ensuring post-close success.

By the time a strategic acquirer enters due diligence, the desire to do the deal is already high. The process's primary purpose is not to hunt for deal-breakers but to confirm key assumptions and, more importantly, to gather the necessary data to build a robust and successful integration plan.

Mergers and acquisitions are a means to accelerate a pre-existing strategy, not the objective itself. When conditions for a deal change unexpectedly, disciplined leaders must be willing to pivot from a full merger to a passive stake rather than force a flawed integration or admit defeat.

When establishing a new M&A function, the primary challenge is getting senior leaders to move beyond broad statements and make concrete strategic choices about which opportunities to actively ignore. This focus is crucial for effective execution and prevents wasted energy on opportunistic, unfocused deals.

Instead of a linear process, treat M&A as a spiral. Constantly revisit and adjust deal structure, diligence findings, and integration plans. A discovery in one area (e.g., diligence) should trigger a reassessment of the others (e.g., deal structure), ensuring a cohesive and de-risked outcome.

The current biotech M&A boom is less about frantically plugging near-term patent cliff gaps (e.g., 2026-2027) and more about building long-term, strategic franchises. This forward-looking approach allows big pharma to acquire earlier-stage platforms and assets, signaling a healthier, more sustainable M&A environment.

The acquisition of SC Pharma was driven less by the product itself and more by a strategic imperative to shift from a royalty-dependent model to one where MannKind controls the majority of its revenue. This gives them direct influence over their growth trajectory and aligns with shareholder desire for self-determination.

After making 13 acquisitions, Deel's CEO learned that the deals that didn't work well were those approached with a 'why not?' attitude. These were often opportunistic plays on adjacent but non-core businesses. Now, he has a simple filter: if an inbound acquisition opportunity isn't an immediate and enthusiastic 'hell yeah,' he passes, avoiding the distraction and integration challenges.